Global Blood Screening Market Size study & Forecast, by Technology (Nucleic Acid Amplification Test, ELISA, Western Blotting), by Product (Reagent, Instrument) and Regional Forecasts 2025-2035

The Global Blood Screening Market, valued at approximately USD 3.4 billion in 2024, is projected to expand at a compelling CAGR of 11.90% from 2025 to 2035. Blood screening, an indispensable process in modern healthcare systems, plays a pivotal role in detecting infectious agents and safeguarding patients from transfusion-transmissible infections. It involves the use of highly sophisticated testing technologies that ensure donated blood is free from pathogens such as HIV, hepatitis viruses, and syphilis. The market’s momentum is being propelled by the escalating demand for safe blood transfusions, driven by the rising incidence of chronic diseases, surgical interventions, and trauma-related procedures worldwide. Furthermore, the expansion of healthcare infrastructure in emerging economies and government-led initiatives to enforce mandatory blood testing are adding to the sector’s upward trajectory.

Over the past decade, the pace of innovation in blood screening technology has intensified, enabling healthcare providers to achieve higher sensitivity and specificity in their testing protocols. Techniques such as Nucleic Acid Amplification Testing (NAT) have emerged as game-changers, drastically reducing the diagnostic window for infectious agents and minimizing the risk of transmission. According to WHO data, the demand for blood components continues to surge in line with the aging global population and increasing prevalence of diseases that necessitate transfusions. However, the industry is not without challenges. The high cost of advanced screening instruments, coupled with stringent regulatory frameworks, can hinder rapid adoption, especially in low-resource settings. Nevertheless, with the integration of automation, AI-driven diagnostic platforms, and the expansion of private-public healthcare partnerships, lucrative opportunities are on the horizon for both established players and new entrants.

From a geographical perspective, North America held a dominant market share in 2025, fueled by its robust healthcare system, high awareness about transfusion safety, and early adoption of cutting-edge diagnostics. The presence of key market players and favorable reimbursement policies have further fortified the region’s leadership position. Europe closely follows, supported by stringent regulatory mandates, well-established blood banks, and advanced laboratory capabilities. Meanwhile, the Asia Pacific region is projected to record the fastest growth during the forecast period, driven by a surge in healthcare investments, rising blood donation rates, and the growing burden of infectious diseases in countries like India and China. Government campaigns to improve blood safety standards, along with investments in modernizing diagnostic laboratories, are expected to amplify the market’s expansion in this region. Latin America and the Middle East & Africa are also showing steady growth, albeit at a slower pace, as infrastructure improvements and awareness campaigns begin to take root.

Major market players included in this report are:
• Hoffmann-La Roche Ltd.
• Abbott Laboratories
• Bio-Rad Laboratories, Inc.
• Grifols, S.A.
• Siemens Healthineers AG
• Thermo Fisher Scientific Inc.
• Ortho Clinical Diagnostics
• Becton, Dickinson and Company
• Beckman Coulter, Inc.
• QIAGEN N.V.
• Danaher Corporation
• Merck KGaA
• PerkinElmer Inc.
• Biomerieux SA
• Agilent Technologies, Inc.

Global Blood Screening Market Report Scope:
• Historical Data – 2023, 2024
• Base Year for Estimation – 2024
• Forecast period – 2025-2035
• Report Coverage – Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
• Regional Scope – North America; Europe; Asia Pacific; Latin America; Middle East & Africa

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values for the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within the countries involved in the study. The report also provides detailed information about crucial aspects, such as driving factors and challenges, which will define the future growth of the market. Additionally, it incorporates potential opportunities in micro-markets for stakeholders to invest, along with a detailed analysis of the competitive landscape and product offerings of key players.

The detailed segments and sub-segments of the market are explained below:

By Technology:
• Nucleic Acid Amplification Test
• ELISA
• Western Blotting

By Product:
• Reagent
• Instrument

By Region:

North America
• U.S.
• Canada

Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE

Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC

Latin America
• Brazil
• Mexico

Middle East & Africa
• UAE
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa

Key Takeaways:
• Market Estimates & Forecast for 10 years from 2025 to 2035.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions. Show more